<DOC>
	<DOCNO>NCT01038843</DOCNO>
	<brief_summary>To investigate effect VA106483 nocturia relate clinical outcome compare placebo .</brief_summary>
	<brief_title>Efficacy Study VA106483 Males With Nocturia .</brief_title>
	<detailed_description>Nocturia , define wake urinate least per night period sleep , common complaint increase age . VA106483 non-peptide drug VA106483 develop treatment nocturia male . The purpose study investigate effect VA106483 number time subject need get urinate ( nocturnal void ) per night determine effect time subject 's bedtime time first wake urinate .</detailed_description>
	<mesh_term>Nocturia</mesh_term>
	<criteria>Male subject age ≥18 year ( upper limit ) nocturia Generally well ( concomitant illness/conditions well control ) Serum sodium within normal limit Normal clinically significant prostate specific antigen level Able comply requirement study Provide write informed consent Prostatic cancer Signs symptom heart failure Peripheral pitting oedema extend ≥10 cm ankle Palpable bladder pelvic mass abdominal examination Enuresis nighttime incontinence Excessive nocturnal void frequency Sleep disorder Diabetes insipidus uncontrolled diabetes mellitus Presence blood glucose urine urinalysis clinically significant Urinary tract infection Polydipsia Syndrome inappropriate antidiuretic hormone secretion Body mass index ≥35 High calcium level low potassium level Other protocol define eligibility criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>VA106483</keyword>
	<keyword>Nocturia</keyword>
	<keyword>male</keyword>
	<keyword>nocturnal void</keyword>
	<keyword>anti-diuretic</keyword>
	<keyword>hyponatraemia</keyword>
</DOC>